Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: herpes simplex virus type 2 vaccines - Genocea Biosciences

Drug Profile

Research programme: herpes simplex virus type 2 vaccines - Genocea Biosciences

Alternative Names: GEN-002; HSV-2 prophylactic (Px) vaccine - Genocea Biosciences; HSV-2 Px; ICP4383-766 + gD2; ICP4383-766 + TMR341-363; ICP4383-766 and gD2

Latest Information Update: 27 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fred Hutchinson Cancer Research Center; Genocea Biosciences; University of Washington
  • Developer Genocea Biosciences
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Herpes simplex virus type 2 infections

Most Recent Events

  • 20 May 2022 Discontinued - Preclinical for Herpes simplex virus type 2 infections (Prevention) in USA (Parenteral) (Genocea Biosciences pipeline, March 2023)
  • 28 Dec 2021 No recent reports of development identified for preclinical development in Herpes simplex virus type-2 infections(Prevention) in USA (Parenteral)
  • 01 Mar 2019 Preclinical development is ongoing in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top